EASL’s International Liver Congress™ (ILC) 2022 will be taking place in London, UK, 22–26 June 2022. Delegates can attend in person or remotely. This first-in-class, international event is running for the 57th time and is the largest annual event on…
14 September 2021 On 16 October 2021, the best of ILC 2021 will be showcased at an online event jointly run by EASL and the Turkish Association for the Study of the Liver (TASL), called the Best of EASL ILC at TASL: Clinical Innovations…
26 August 2021 On 10 July 2021, the Journal of Hepatology published a new free-access EASL Position Paper, titled, “Systemic treatment of hepatocellular carcinoma”, by Jordi Bruix et al.
18 August 2021 The International Liver Congress™ gives EASL a golden opportunity to engage with international journalists, reaching media in multiple languages, all over the world. This year was no exception.
We would like to thank every single participant who took part in this year's ILC, held 23–26 June 2021. The event brought together almost 6,500 delegates from over 100 countries, who took part in 155 sessions, listened to 566 presentations…
For Immediate Release Media Release Treatment advances for Non-Alcoholic Fatty Liver Disease (NAFLD) announced at ILC 2021 New data released on trials involving RNAi therapeutics, antivirals and structurally engineered fatty acids to treat NAFLD Friday 25 June 2021 (Geneva, Switzerland)--…
In EASL Studio, we were honoured to keep company with the three 2020 Nobel Laureates, awarded the 2020 Nobel Prize for Physiology and Medicine for their discovery of the hepatitis C virus. They reflected on many thought-provoking topics: the exponential…
For Immediate Release Media Release Advances in new drugs to for curing Hepatitis B and Hepatitis D announced at ILC 2021 Thursday 24 June 2021 (Geneva, Switzerland)-- Leading hepatology researchers announced important new developments in hepatitis research at the International…
For Immediate Release Media Release ILC 2021 opens with focus on impact of COVID-19 on global liver disease New data demonstrates that chronic liver disease increased the odds of COVID-19 death by 80% and Pfizer-BioNTech COVID-19 vaccine confers low immunity on people with advanced…
